Calvo-Castro Jesus, Guirguis Amira, Samaras Eleftherios G, Zloh Mire, Kirton Stewart B, Stair Jacqueline L
Department of Pharmacy, Pharmacology and Postgraduate Medicine, School of Life and Medical Sciences, University of Hertfordshire Hatfield AL10 9AB UK
RSC Adv. 2018 Sep 12;8(56):31924-31933. doi: 10.1039/c8ra05847d.
A novel approach for the identification of New Psychoactive Substances (NPS) by means of Raman spectroscopy coupled with Principal Components Analysis (PCA) employing the largest dataset of NPS reference materials to date is reported here. Fifty three NPS were selected as a structurally diverse subset from an original dataset of 478 NPS compounds. The Raman spectral profiles were experimentally acquired for all 53 substances, evaluated using a number of pre-processing techniques, and used to generate a PCA model. The optimum model system used a relatively narrow spectral range (1300-1750 cm) and accounted for 37% of the variance in the dataset using the first three principal components, despite the large structural diversity inherent in the NPS subset. Nonetheless, structurally similar NPS (, the synthetic cannabinoids FDU-PB-22 & NM-2201) grouped together in the PCA model based on their Raman spectral profiles, while NPS with different chemical scaffolds (, the benzodiazepine flubromazolam and the cathinone α-PBT) were well delineated, occupying markedly different areas of the three-dimensional scores plot. Classification of NPS based on their Raman spectra (, chemical scaffolds) using the PCA model was further investigated. NPS that were present in the initial dataset of 478 NPS but were not part of the selected 53 training set (validation set) were observed to be closely aligned to structurally similar NPS within the generated model system in all cases. Furthermore, NPS that were not present in the original dataset of 478 NPS (test set) were also shown to group as expected in the model (, methamphetamine and -ethylamphetamine). This indicates that, for the first time, a model system can be applied to potential 'unknown' psychoactive substances, which are new to the market and absent from existing chemical libraries, to identify key structural features to make a preliminary classification. Consequently, it is anticipated that this study will be of interest to the broad scientific audience working with large structurally diverse chemical datasets and particularly to law enforcement agencies and associated scientific analytical bodies worldwide investigating the development of novel identification methodologies for psychoactive substances.
本文报道了一种通过拉曼光谱结合主成分分析(PCA)来鉴定新型精神活性物质(NPS)的新方法,该方法使用了迄今为止最大的NPS参考材料数据集。从478种NPS化合物的原始数据集中选择了53种NPS作为结构多样的子集。对所有53种物质进行了拉曼光谱轮廓的实验采集,使用多种预处理技术进行评估,并用于生成PCA模型。尽管NPS子集中存在较大的结构多样性,但最佳模型系统使用了相对较窄的光谱范围(1300 - 1750 cm),并使用前三个主成分解释了数据集中37%的方差。尽管如此,结构相似的NPS(如合成大麻素FDU - PB - 22和NM - 2201)在PCA模型中根据其拉曼光谱轮廓聚集在一起,而具有不同化学骨架的NPS(如苯二氮卓类氟溴马唑仑和卡西酮α - PBT)则被清晰区分,占据三维得分图中明显不同的区域。进一步研究了使用PCA模型基于NPS的拉曼光谱(即化学骨架)对其进行分类。在所有情况下,观察到初始数据集中478种NPS中存在但不属于选定的53种训练集(验证集)的NPS与生成的模型系统内结构相似的NPS紧密对齐。此外,在478种NPS原始数据集中不存在的NPS(测试集),如甲基苯丙胺和乙基苯丙胺,在模型中也如预期那样聚集在一起。这表明,首次可以将一个模型系统应用于市场上新出现且现有化学库中不存在的潜在“未知”精神活性物质,以识别关键结构特征进行初步分类。因此,预计这项研究将引起处理结构多样的大型化学数据集的广大科学界的兴趣,特别是引起全球范围内调查精神活性物质新型鉴定方法发展的执法机构和相关科学分析机构的兴趣。